公开(公告)号：US20230242647A1

公开(公告)日：2023-08-03

申请号：US17997482

申请日：2021-04-29

Applicant: Novartis AG

Inventor： John BLANKENSHIP ,  Justine Celine Patricia GUYOT ,  Brian HOLMBERG ,  Sebastien IRIGARAY ,  Darko SKEGRO

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00

CPC classification number: C07K16/283 ,  A61K39/3955 ,  A61P35/00 ,  A61K2039/505

Abstract: The present invention provides engineered immunoglobulins or fragments thereof and methods for their preparation and uses. The engineered immunoglobulins have been derived from human IgG1 and engineered to confer Fc alpha receptor binding ability. In addition, the engineered IgG1 immunoglobulins or fragments thereof can retain binding to Fc gamma receptors and/or FcRn.

公开(公告)号：US20230295322A1

公开(公告)日：2023-09-21

申请号：US17934064

申请日：2022-09-21

Applicant: NOVARTIS AG

Inventor： Aida ABUJOUB ,  John BLANKENSHIP ,  Tony FLEMING ,  Brian HOLMBERG ,  Connie HONG ,  Lu HUANG ,  Haihui LU

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  C07K16/46 ,  A61K39/395

CPC classification number: C07K16/2878 ,  A61K47/6803 ,  A61K47/6849 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/468 ,  A61K39/3955 ,  C07K16/2896 ,  C07K16/2866 ,  C07K16/283 ,  A61K2039/505

Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.

公开(公告)号：US20220332821A1

公开(公告)日：2022-10-20

申请号：US17620987

申请日：2020-06-22

Applicant: NOVARTIS AG

Inventor： Kimberly AARDALEN ,  Aida ABUJOUB ,  John BLANKENSHIP ,  Anuradha CONNOR ,  Mirek DOSTALEK ,  Tony FLEMING ,  Brian HOLMBERG ,  Connie HONG ,  Lu HUANG ,  Haihui LU ,  K. Gary J. VANASSE

IPC: C07K16/28 ,  A61P35/00 ,  A61K9/00 ,  A61K31/167 ,  A61K31/417 ,  A61K31/56

Abstract: The present disclosure relates to dosing regimens, formulations, and combinations comprising a multispecific antibody having at least binding specificity towards B cell maturation antigen (BCMA) and a T-cell engaging arm; and methods of using such multispecific antibodies in the treatment or prevention of disease, such as, cancer.

公开(公告)号：US20230167193A1

公开(公告)日：2023-06-01

申请号：US17997485

申请日：2021-04-29

Applicant: Novartis AG

Inventor： John BLANKENSHIP ,  Justine Celine Patricia GUYOT ,  Brian HOLMBERG ,  Sebastien IRIGARAY ,  Darko SKEGRO

IPC: C07K16/30

CPC classification number: C07K16/30 ,  C07K2317/732 ,  A61K2039/505

Abstract: The present invention provides an Fc variant of a parent IgA Fc polypeptide, wherein the Fc variant exhibits altered binding to FcαRs, wherein the Fc variant comprises at least one amino acid modification in the Fc region of the parent Fc polypeptide.